Sep 10, 2020 11:19:00

Vaccine trial of new corona suspended due to 'spinal cord problem', AstraZeneca announced that 'patients can be discharged early'

AstraZeneca said that the clinical trial of the new coronavirus infection (COVID-19) vaccine ' ChAdOx1 nCoV-19 (AZD1222) ' developed by the British pharmaceutical company AstraZeneca was interrupted due to the occurrence of unexpected symptoms. 'The symptom was an inflammatory disease of the spinal cord,' he said. According to the company, women with symptoms are recovering and are expected to be discharged soon.

AstraZeneca CEO says attended neurological symptoms, could be discharged today
https://www.statnews.com/2020/09/09/astrazeneca-covid19-vaccine-trial-hold-patient-report/

In July 2020, AstraZeneca announced the COVID-19 vaccine 'AZD1222' jointly developed with Oxford University in the United Kingdom. With a promising 100% immunity acquisition rate and no serious side effects, we started a large-scale phase III clinical trial in late August.

However, the trial was suspended because a British woman who was attending the trial on September 8, local time, presented with 'unexplained symptoms.' AstraZeneca's clinical trials revealed problems, including nine pharmaceutical and biotechnology companies, including AstraZeneca, confirming the policy of prioritizing vaccine safety and rigorous clinical trials. It was the same day that the joint signature was released .

Clinical trial of new coronavirus vaccine suspended as 'a case of suspected side effect occurred' --GIGAZINE

Pascal Soriot, CEO of AstraZeneca, said in a telephone conference for investors on September 9, 'The symptom of a British woman (who had the symptom of the problem) is the extremely rare and serious spinal cord of transverse myelitis. He had neurological symptoms consistent with his inflammatory disease. ' Francis Collins, director of the National Institutes of Health, has a similar view .

According to Solio's report, the woman's diagnosis has not yet been confirmed, but her symptoms have improved and she is likely to be discharged as early as nine days.

In a conference call, Solio also revealed that AstraZeneca's clinical trials had been suspended due to a neuropathy in late July. Later investigations diagnosed multiple sclerosis as the symptom that caused the study to be discontinued, but it is believed to be unrelated to the vaccine.

Investors attending the conference call told STAT, a news site specializing in medical information, 'Mr. Solio's statement was intended to reassure investors and eliminate the impact on the company's stock price.' ..

STAT also noted that AstraZeneca did not publicize the issue of clinical trials being suspended in late July. 'So far, the official statement regarding the suspension of AstraZeneca's trial has been neglected. For example, the company has canceled the trial for the second time to investigate the health of participants. We haven't officially announced that there is something. '

According to STAT, it is not clear how long AstraZeneca's Phase III clinical trials will be suspended.